EMA Requests Immediate Recall of MS Drug Daclizumab (Zinbryta)

Share this post

Just days after the company announced voluntary withdrawal of the drug, the EMA recommends immediate suspension and recall of daclizumab in multiple sclerosis.
News Alerts

This post was syndicated from Medscape Medical News Headlines. Click here to read the full text on the original website.

Share this post

Be the first to comment

Leave a Reply